文献速递乳腺技术与安全PETCT

Dotatate PET/CT与225Ac-Dotatate治疗生长抑素受体表达的转移性乳腺癌

Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer.
PubMed 文献 · Radiology · 2024-01-01

本研究先以组织微阵列分析乳腺癌SSTR2表达,发现ER阳性样本中51%富集SSTR2而ER阴性样本仅18%,随后在前瞻性2期试验中对30例转移性ER阳性乳腺癌患者行Dotatate PET/CT,30%患者肿瘤Krenning评分3或4,1例Krenning 4患者接受225Ac-Dotatate治疗后接近完全缓解。

要点

  • ER阳性乳腺癌组织SSTR2富集比例51%,显著高于ER阴性的18%。
  • 转移性ER阳性乳腺癌患者Dotatate PET/CT阳性率30%,即Krenning评分3或4。
  • Krenning评分3为摄取高于肝脏,4为摄取高于脾脏。

核心结论

  • 靶向SSTR2的分子影像与225Ac-Dotatate放射配体治疗为转移性乳腺癌患者提供了一种新的治疗选择。

研究设计与样本

  • 临床前组织微阵列分析评估乳腺癌样本SSTR2表达,H-score高于50(0-300量表)为阳性;随后为前瞻性2期临床试验,2023年1月至8月纳入30例活检证实的ER阳性转移性乳腺癌女性患者(平均年龄66岁±15)行Dotatate PET/CT,其中1例Krenning 4患者接受225Ac-Dotatate治疗。

诊断标准与关键数值

  • Dotatate PET/CT阳性定义为肿瘤Krenning评分3(摄取高于肝脏)或4(摄取高于脾脏);30例中9例(30%[95%CI:15,49])为阳性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Somatostatin receptors, and specifically somatostatin receptor type 2 (SSTR2), have primarily been associated with neuroendocrine tumors and have revolutionized the imaging and therapy of patients with these tumors. SSTR2 is expressed on other tumors at lower prevalence. Purpose To evaluate the potential of SSTR2-targeted imaging and therapy in patients with breast cancer. Materials and Methods In a preclinical experiment, SSTR2 expression was assessed in tissue microarrays of breast cancer samples using H-score analysis. H-scores higher than 50 (0-300 scale) were considered positive. Then, a prospective phase 2 clinical trial of SSTR2-targeted tetraazacyclododecane tetraacetic acid octreotate (Dotatate) PET/CT was performed in participants with biopsy-proven estrogen receptor (ER)-positive breast cancer from January to August 2023. A positive Dotatate PET/CT scan was defined as tumors with a Krenning score of 3 (avidity greater than liver) or 4 (avidity greater than spleen). The proportion of positive scans and the 95% CI were calculated. One participant with metastatic ER-positive breast cancer and a Krenning 4 Dotatate PET/CT result underwent treatment with SSTR2-targeted actinium 225 (225Ac) Dotatate. Results Preclinical microarrays demonstrated that 63 of 123 ER-positive breast cancer tissue samples (51% [95% CI: 42, 60]) but only 22 of 121 ER-negative breast cancer tissue samples (18% [95% CI: 12, 26]) were enriched for SSTR2 (P < .001). Thirty female participants (mean age, 66 years ± 15) with metastatic ER-positive breast cancer were accrued to the phase 2 SSTR2-targeted imaging trial and underwent Dotatate PET/CT. Dotatate PET/CT demonstrated that nine of 30 participants (30% [95% CI: 15, 49]) had tumors with Krenning scores of 3 or 4, indicating strong SSTR2 expression. SSTR2-targeted therapy with alpha-emitting 225Ac-Dotatate resulted in a near complete response in a heavily pretreated participant with metastatic ER-positive breast cancer and a Krenning 4 Dotatate PET result. Conclusion Molecular imaging targeting SSTR2 and radioligand therapy with SSTR2-targeted 225Ac-Dotatate enables a new therapeutic option for patients with metastatic breast cancer. Clinical trial registration no. NCT05880394 © RSNA, 2024 See also the editorial by Lin and Choyke in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ulaner GA, VanderMolen LA, Li G, et al. Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer. Radiology. 2024. PMID: 39078299. doi:10.1148/radiol.233408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。